"Nephrotoxicity is a serious and potentially life-threatening adverse effect associated with the antiviral agents cidofovir and tenofovir. Through the application of our proprietary PIM Conjugate Technology we are able to dramatically alter drug distribution and thereby potentially avoid nephrotoxicity," said George Painter, Ph.D., Chief Scientific Officer of Chimerix. "Our animal and clinical studies of CMX001 and CMX157, in which both compounds have demonstrated a positive safety profile, are consistent with our in vitro observations that CMX001 and CMX157 are not metabolized in the kidney. Furthermore, these data are consistent with, and provide a mechanistic explanation for, data presented at the recent ICAAC meeting that CMX001 was well tolerated in 46 patients with compromised renal function."
Chimerix is developing CMX001 for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viruses in immunocompromised transplant and cancer patients and as a medical countermeasure in the event of a smallpox release. CMX001 is currently in Phase 2 clinical trials for the prophylaxis and treatment of human cytomegalovirus infection. CMX157 is currently in Phase 1 clinical testing for the treatment of HIV infections.
Cidofovir and tenofovir are polar, acyclic nucleoside phosphonates that are FDA-approved as Vistide® (cidofovir injection) f
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved